

Irit Avivi^{1,2}, Chava Perry^{1,2}, Orli Greenberg^{2,3}, Neta Hershkovitz⁴, Dov Hershkovitz^{2,3}, Assaf Avinoam⁵, Ido Hayun⁵, Inbal Gazy⁵, Nurit Paz-Yaacov⁵

¹ Hematology department, Tel Aviv Sourasky Medical Center, ² Sackler Faculty of Medicine, Tel Aviv University, ³ Pathology department, Tel Aviv Sourasky Medical Center, ⁴ Hematology department, Tel Aviv Medical Center, ⁵ Imagene AI, Tel Aviv, Israel

INTRODUCTION


- Aggressive B-cell Non-Hodgkin Lymphomas (B-NHL) are divided into two main categories:
 - Diffuse large B-cell lymphoma (DLBCL) accounting for 90% of cases
 - High-grade B-cell lymphoma (HGBL)
- Diagnosis of HGBL with *MYC* and *BCL2* and/or *BCL6* rearrangements (double-hit lymphoma; DH-L) is confirmed by fluorescence in situ hybridization (FISH) analysis¹.
- Accurate and rapid diagnosis of DH-L is obligatory, when considering more aggressive treatment regimens (other than R-CHOP), suggested in these patients².

OBJECTIVE

To establish a novel tool for diagnosing DH-L directly from scanned Hematoxylin and Eosin (H&E) biopsy slides, by applying digital imaging technologies supported by machine learning algorithms.

METHOD

- H&E whole slide images (WSIs), prepared from biopsies obtained from lymph nodes as well as extra-nodal organs of patients with aggressive B-cell lymphoma histology, were collected from the pathology department at Tel-Aviv Sourasky Medical center (TASMC).
- Advanced Convolutional Neural Network (CNN) analysis was used to generate the aggressive B-NHL classifier (powered by Imagene-AI).



STUDY COHORT

- Cases were randomly divided into a training and a validation set (no significant differences were found between the sets).

Patients characteristics

	Training set (n=33)	Validation set (n=26)
Male, n (%)	18 (54.5)	16 (61.5)
GCB, n (%)	13 (39.4)	14 (53.8)
Lymph node samples, n (%)	14 (42.4)	6 (23.1)
Extra nodal samples, n (%)	19 (57.6)	20 (76.9)

RESULTS


- H&E WSIs of the validation set samples were analysed using the AI-DH-L Classifier.
- The Classifier performance was evaluated compared to the official results obtained by FISH analysis.

AI-DH-L Classifier performance

Total	Official results		AI-Classifier results				AI-Classifier performance			
	# P	# N	# TP	# TN	# FP	# FN	Sensitivity	Specificity	Accuracy	AUC
26	10	16	9	14	2	1	90%	87.5%	88.46%	0.94

P=positive, N=negative, TN=true negative, TP=true positive, FP=false positive, FN=false negative

- Current criteria for employing FISH analysis to detect DH-L cases rely on **Ki67** expression, **MYC** expression, or diagnosis of **GCB**. However, all were found to be insufficiently specific³.
- The AI-DH-L Classifier demonstrated high predictive values as a screening tool.



Predictive values of conventional features vs. the AI-DH-L-classifier for correctly deciding whether to perform FISH testing.
Presented are the number of samples in the relevant bars and predictive values for each screening method used (bright red and dark green bars).

CONCLUSIONS

- Here we present an AI-solution for the identification of DH-L patients.
- Current features used as criteria for FISH testing for the detection of DH-L cases display unacceptable rates of false negative cases demanding the development of new screening methods.
- The AI-DH-L Classifier demonstrated high performances and displayed superior predictive values compared to current conventional criteria used as a screening tool for guiding FISH testing.
- Interestingly, the AI-DH-L Classifier identified 2 cases with complex Burkitt manifestation and FISH results as DH-positive. While requiring further investigation, this suggests that the Classifier might identify cases that otherwise would have not been identified as DH with the conventional methods.

VISION

- Image-based prediction of biomarker status provides a fast, accessible and standardized method.
- The AI solution presented here uses routinely prepared pathological slides for the prediction of biomarker status without the requirement for additional material or substantial human labor.
- Implementation of such a system within the medical center can support real-time molecular profiling of B-NHL patients, defining a specific group of patients that would benefit from subsequent FISH testing, thereby, ultimately improving patient care.

REFERENCES

- Swerdlow SH *et al.* Blood, 2016, 127:2375-90
- Phuoc V *et al.* Drugs in Context, 2019, 8:2019-8-1
- Landsburg DJ and Schuster SJ, J Oncol Pract , 2016, 12:243-4

CONTACT INFORMATION

Irit Avivi: iritavi@tlvmc.gov.il

www.imagene-ai.com